Dissertation > Excellent graduate degree dissertation topics show

Primary Investigation of ProMACE-CytaBOM Modified Regimen in Treating Relapsed or Refractory Aggressive NHL

Author: ZuoYanYing
Tutor: HuXiaoZuo
School: Guangxi Medical University
Course: Oncology
Keywords: ProMACE-CytaBOM program Improve Relapsed or refractory aggressive NHL
CLC: R733.1
Type: Master's thesis
Year: 2011
Downloads: 7
Quote: 0
Read: Download Dissertation

Abstract


Objective: relapsed or refractory aggressive NHL is not yet a standard regimen. The purpose of this study to conventional programs explore ProMACE-CytaBOM improved after the treatment of recurrent, refractory aggressive NHL, efficacy and safety. Methods: We analyzed the period from December 2001 to September 2010, our hospital treated 41 patients with relapsed and refractory lymphoma patients, the use of conventional and improved chemotherapy ProMACE-CytaBOM, conventional regimen group, 20 patients; improvement program group of 21 patients . Conventional regimen group administered: cyclophosphamide 650 mg / m ~ 2, intravenous injection, the first day; doxorubicin 30 mg / m ~~ 2 or epirubicin than the star of 40 mg / m to 2, intravenous, days; etoposide 120 mg / m to 2, intravenous injection, the first day; prednisone 60 mg / m ~ 2, Dayton clothing, 1 to 14 days; cytarabine 300 mg / m ~~ 2 intravenous injection, 8 days; Bleomycin 10 mg / m to 2 intravenously on day 8; vincristine 1.4 mg / m 2 intravenously, day 8; methotrexate 120mg / m - intravenous, 8 days; leucovorin 15 mg / m ~~ intravenous (MTX intravenously after 24 h), once every 6 hours, 6 times; 21 days of a cycle. Improvement program group to adjust medication: prednisone 60 mg / m ~ 2, Dayton clothing, 1 to 5 days; methotrexate ≥ 1g / m ~ 2, intravenous injection, 8 days; Other administered the same way as conventional program group. The recent efficacy analysis of the two programs, the long-term efficacy and adverse reactions, SPSS17.0 analysis, constitute a group than the chi-square test and the fourfold table Fisher exact test, measurement data using t test; Kaplan-Meier method to draw the survival curve Comparative Analysis of the Long-rank test was used for survival between the two groups. All P values ??are two-sided test. Results: 20 cases of patients in conventional programs ORR was 60.0% (CR 35%); median progression-free survival (1.1 to 6.9), and median overall survival was 21 (9.4 to 32.6) months . 21 cases of patients using a modified program ORR was 66.7% (CR 23.8%); median progression-free survival was 5.5 (1.8 to 9.2), and median overall survival was 17 months (13.0 to 21.0) months . The overall efficacy of the two programs and the prognosis was no significant difference (P gt; 0.05). Conventional and improved program between the two groups in median progression-free survival of patients with normal LDH (2 vs 8), B symptoms (1.5 vs 3) difference was statistically significant (P lt; 0.05), progression-free survival function curve improvement programs are better than conventional programs; conventional and improved program group median overall survival in the Phase Ⅱ (32 vs 58), LDH normal patients (15 vs 49), patients with B symptoms (4 vs 16) the difference was statistically significance (P lt; 0.05), survival function curves to show improvement programs are better than conventional programs; remaining subgroup conventional programs and improvement programs in progression-free survival and overall survival period was no statistical difference in survival function curve approaching. Two sets of common chemotherapy adverse hematologic toxicity and grade Ⅰ ~ Ⅱ Ⅱ ~ Ⅲ degree of nausea, vomiting, mucosal go far non-hematologic adverse reactions, can be tolerated, no statistically significant difference between the two groups; glucocorticoid hormone-related adverse reactions, improved scheme is lower than the conventional scheme. Conclusion: ProMACE-CytaBOM conventional programs and improved program treatment of relapsed refractory aggressive NHL is effective and acceptable side effects for patients with relapsed or refractory aggressive lymphoma B symptoms should be based on the staging, IPI index, LDH values ??take stratification, individualized treatment. In this study, the modified program, did not reduce the efficacy and reduce hormone-related adverse reactions. The study also worth further exploration.

Related Dissertations

  1. "Small Group" Model to Improve Teaching Aerobics Girls Vocational Colleges Mental Health Research,G831.3
  2. F enterprises with RFID data capture products to improve i Research and Application,TP274.2
  3. The definition and punishment of Unit Crime,D924.1
  4. On Criminal Summary Procedure,D925.2
  5. Research on Our Country’s Legal System of Rural Social Assistance,D422.6
  6. On the status quo of our mortgage legislation , issues and improvement,F293.3
  7. Improvement Study of Packaging Line Base on Six Sigma,F273
  8. Local Normal Colleges transition issues of professional settings,G652.4
  9. The Effect of Pentylmethylquercetin in Metabolic Syndrome Mice Due to Intervention of Monosodium Glutamate,R285.5
  10. The Application of Schema Theory in Senior High English Vocabulary Teaching,G633.41
  11. Weak in poor rural areas and improvement of junior status,G639.2
  12. Research on the Reform of the Initiator of Criminal Judicial Expertise,D925.2
  13. WAA Clinical observation of treatment of frozen shoulder,R246
  14. Junior Middle School Physics Demonstration Experiment Teaching Improvement Research,G633.7
  15. Improve the Junior High School Students Interested in Learning Chemistry Research,G633.8
  16. Product Design Based on Quality Function Deployment,F273.2
  17. Pplication Study of Six Sigma in Supplier Quality Management,F273
  18. Research on Corporate Social Responsibility in Economic Law,F270
  19. Improve the Tax Collection System after the Real Estate Market and Countermeasures,F293.3
  20. Design and Implementation of Office Automation System Based on Collaborative Web Network,TP317.1
  21. The county-level people's congresses motion suggests that the work of,D624

CLC: > Medicine, health > Oncology > Hematopoietic and lymphoid neoplasms > Reticuloendothelial system tumors
© 2012 www.DissertationTopic.Net  Mobile